QUANTIFY is an experienced global partner in health economics & outcomes research (HEOR), market access (MA) and other activities related to patient access. Our top priority is to provide high quality services that add value throughout the drug commercialization process by utilizing our unique experience and skillsets. Our core service offerings include:




The value of any drug, device, procedure or reform in health care is dependent on the medical need it is intended to meet, its alternatives, and the perspectives of its stakeholders.

Learn more


A wide range of methods and data sources can be used and combined to quantify the value of health care interventions and meet the evidence requirements of the stakeholders.

Learn more


The communication of study results needs to be carefully considered to ensure that the key messages are presented in a clear and convincing way.

Learn more

Make the complex simple


25Jan 2022

Looking for an experienced partner to support your evidence generation strategy? Welcome to Quantify!

Last week, ISPOR released their 2022–2023 Top 10 Health Economics and Outcomes Research Trends Report, highlighting high-impact trends in healthcare. These include real world evidence, drug and healthcare pricing, health technology assessment, health data, and artificial intelligence. QUANTIFY is proud to offer experience and expertise in these areas – get in touch with us today to hear more about how we […]

19Jan 2022

Patients with atopic dermatitis can be accurately identified by algorithm

Quantify’s Gustaf Ortsäter, Kirk Geale and Alexander Rieem Dun have published an observational cohort study which validates an algorithm using skin-specific diagnoses from secondary care and pharmacy-dispensed prescriptions to identify patients with atopic dermatitis.

The study shows that pediatric patients with atopic dermatitis can be accurately identified by the algorithm, but further adjustments are required to identify adult patients. This work is important for future studies that […]

11Jan 2022

Alzheimer’s disease in a Swedish context

Sweden is a pioneer country when it comes to Alzheimer’s research, and great progress has been made in recent years. Head on over to https://lnkd.in/gVNBKAJd to read an interview with Quantify partner Anders Gustavsson and Karolinska institutet professor Bengt Winblad, on their white paper on Alzheimer’s disease in a Swedish context. (all texts in Swedish).

#RWE #MarketAccess #HEOR #datascience